Unlock stock picks and a broker-level newsfeed that powers Wall Street.

3 US Penny Stocks With Market Caps Larger Than $50M

In This Article:

As investors digest a flurry of earnings reports, stock futures are pointing to a lower open for major U.S. indexes, reflecting the ongoing volatility and mixed sentiment in the market. For those exploring investment opportunities beyond the traditional large-cap stocks, penny stocks—despite their somewhat outdated name—remain an intriguing area due to their potential for growth and value. In this article, we examine several penny stocks that exhibit strong financial foundations, offering insights into companies that might be overlooked but hold promise for long-term success.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.7988

$5.8M

★★★★★★

LexinFintech Holdings (NasdaqGS:LX)

$3.15

$485.02M

★★★★★★

Flexible Solutions International (NYSEAM:FSI)

$3.47

$45.02M

★★★★★★

RLX Technology (NYSE:RLX)

$1.62

$2.1B

★★★★★★

ARC Document Solutions (NYSE:ARC)

$3.42

$147.91M

★★★★★★

Imperial Petroleum (NasdaqCM:IMPP)

$3.77

$114.05M

★★★★★★

Permianville Royalty Trust (NYSE:PVL)

$1.57

$52.63M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$69.71M

★★★★★★

PHX Minerals (NYSE:PHX)

$3.63

$137.99M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$1.09

$96.23M

★★★★★☆

Click here to see the full list of 752 stocks from our US Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Allakos

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Allakos Inc. is a clinical stage biotechnology company focused on developing therapeutics targeting immunomodulatory receptors on immune effector cells for treating allergy, inflammatory, and proliferative diseases in the United States, with a market cap of $58.64 million.

Operations: Allakos Inc. currently does not report any revenue segments.

Market Cap: $58.64M

Allakos Inc., a pre-revenue biotech company with a market cap of US$58.64 million, is navigating significant challenges typical for penny stocks. Recent Phase 1 results for AK006 showed promising safety and receptor occupancy data, potentially enhancing its therapeutic pipeline. However, the company's shares face delisting risks from Nasdaq due to not meeting the minimum bid price requirement. Financially, Allakos remains unprofitable with a negative return on equity and has experienced shareholder dilution over the past year. Despite having short-term assets exceeding liabilities and being debt-free, its cash runway is limited if current cash flow trends persist.